{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Madrigal Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"MDGL"},"Address":{"label":"Address","value":"200 BARR HARBOR DRIVE,SUITE 200, FOUR TOWER BRIDGE, WEST CONSHOHOCKEN, Pennsylvania, 19428, United States"},"Phone":{"label":"Phone","value":"+1 267 824-2827"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action."},"CompanyUrl":{"label":"Company Url","value":"http://www.madrigalpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Edward Chiang","title":"SVP-Clinical & Technical Operations"},{"name":"Michael R. Charlton","title":"Senior Vice President-Clinical Development"},{"name":"Rebecca A. Taub","title":"Director, President-Research & Development"},{"name":"Ronald Filippo","title":"Chief Information Officer"},{"name":"Stephen Dodge","title":"Senior Vice President-Global Medical Affairs"},{"name":"William J. Sibold","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}